Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
By K. Lai, S. Lam, K. Chu, B. Wong, W. Hui, W. Hu, G. Lau, W. Wong, M. Yuen, A. O. Chan and 2 more. New England Journal of Medicine, 2002
683 citations recorded by the source corpus.
BACKGROUND The role of gastric acid suppression in preventing the recurrence of ulcer complications after the eradication of Helicobacter pylori infection in patients taking long-term low-dose aspirin is uncertain. METHODS We enrolled 123 patients who had ulcer complications after using low-dose aspirin continuously for more than one month and who had H. pylori infection. After the ulcers had healed and the H. pylori infection was eradicated, the patients were randomly assigned to treatment with 30 mg of lansoprazole daily or placebo, in addition to 100 mg of aspirin daily, for 12 months. The primary end point was the recurrence of ulcer complications. RESULTS During a median follow-up of 12 months, 9 of the 61 patients in the placebo group (14.8 percent), as compared with 1 of the 62 patients in the lansoprazole group (1.6 percent), had a recurrence of ulcer complications (adjusted hazard ratio, 9.6; 95 percent confidence interval, 1.2 to 76.1). Of these 10 patients, 4 had evidence of a recurrence of H. pylori infection and 2 had taken nonsteroidal antiinflammatory drugs before the onset of complications. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups. CONCLUSIONS In patients who had ulcer complications related to the long-term use of low-dose aspirin, treatment with lansoprazole in addition to the eradication of H. pylori infection significantly reduced the rate of recurrence of ulcer complications.
Subfields: Cardiology and Cardiovascular Medicine, Pharmacology, Surgery
View Paper: https://www.semanticscholar.org/paper/5166308170762a96008cafdce94cec91bf309280
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Surgery
Citations in the corpus
- [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, background): “RCTs have shown that PPIs reduce the rate of recurrent gastrointestinal bleeding in high-risk patients receiving aspirin [71].”
- Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report (2016, result): “Although H. pylori eradication has been shown to reduce peptic ulcer bleeding in ASA users, 49 – 51 a more recent meta-analysis pointed out that the evidence was not enough to conclude that this infection was a risk factor for peptic ulcer bleeding in ASA users.”
- Management of Patients With Ulcer Bleeding (2012, background): “pylori eradication, recurrent bleeding ulcers occurred with resumption of low-dose aspirin in 15p (”